Business
Pharvaris to Present Deucrictibant Clinical Data and Exploratory Biomarker Data at Upcoming Congresses
ZUG, Switzerland, May 19, 2025 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2
About this update from Pharvaris N.v.
ZUG, Switzerland , May 19, 2025 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS ), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), today announced the acceptance of abstracts for presentation at three upcoming congresses: the 14th C1-Inhibitor Deficiency and Angioedema Workshop , to be held from May 29-June 1, 2025 , in Budapest ; the 2025 Eastern Allergy Conference (EAC), to be held from May 29-June 1, 2025 , in Palm Beach, Fl. ; and the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2025, to be held from June 13-16, 2025 , in Glasgow . Details of the presentations are as follows: C1-Inhibitor Deficiency and Angioedema Workshop , Budapest , May 29-June 1, 2025 . Title: Clinical Validation of a Novel Biomarker Assay to Characterize Bradykinin-Mediated Angioedema in Prospective and Biobank Plasma Samples Presenter: Evangelia Pardali, Ph.D. Format: Oral Presentation, O-02 Date, time: Friday, May 30 , 8:45-9:00 CEST ( 2:45-3:00 a.m. ET ) Title: Long-Term Prophylactic Treatment With Oral Deucrictibant Improves Health-Related Quality of Life and Disease Control in Participants With Hereditary Angioedema: CHAPTER-1 Open-Label Extension Study Presenter: Markus Magerl , M.D. Format: Poster Presentation, P-19 Date, time: Friday, May 30 , 15:45-17:30 CEST ( 9:45-11:30 a.m. ET ) Title: Sustained Therapeutic Exposure with Once-Daily Oral Deucrictibant XR Tablet for Prophylaxis of Hereditary Angioedema Attacks: Results of a Pharmacokinetics Study in Healthy Volunteers Presenter: Zhi-Yi Zhang , Ph.D. Format: Poster Presentation, P-20 Date, time: Friday, May 30 , 15:45-17:30 CEST ( 9:45-11:30 a.m. ET ) Title: Acquired Angioedema Due to C1-Inhibitor Deficiency: Patient Experience and Assessment of Patient-Reported Outcome Measures Presenter: Andrea Zanichelli , M.D., Ph.D. Format: Poster Presentation, P-17 Date, time: Friday, May 30 , 15:45-17:30 CEST ( 9:45-11:30 a.m. ET ) Title: Long-Term Safety and Efficacy of Oral Deucrictibant for Prophylaxis in Hereditary Angioedema: Data Snapshot Results of the CHAPTER-1 Open-Label Extension Study Presenter: Emel Aygören-Pürsün, M.D. Format: Oral Presentation, O-33 Date, time: Saturday, May 31 , 15:30-15:45 CEST ( 9:30-9:45 a.m. ET ) Title: Long-Term Safety and Efficacy of Oral Deucrictibant for Treatment of Hereditary Angioedema Attacks: Results of the RAPIDe-2 Extension Study Presenter: Marc A. Riedl , M.D., M.S. Format: Oral Presentation, O-34 Date, time: Saturday, May 31 , 15:45-16:00 CEST ( 9:45-10:00 a.m. ET ) Title: Durability Of Response to a Single Dose of Oral Deucrictibant for On-Demand Treatment of Hereditary Angioedema Attacks Presenter: Anna Valerieva, M.D., Ph.D. Format: Poster Presentation, P-56 Date, time: Saturday, May 31 , 16:45-17:45 CEST ( 10:45-11:45 a.m. ET ) Title: CHAPTER-3 Phase 3 Trial Design: Efficacy and Safety of the Oral Bradykinin B2 Receptor Antagonist Deucrictibant Extended-Release Tablet for Prophylaxis of Hereditary Angioedema Attacks Presenter: Andrea Zanichelli , M.D., Ph.D. Format: Poster Presentation, P-42 Date, time: Saturday, May 31 , 16:45-17:45 CEST ( 10:45-11:45 a.m. ET ) Title: Safety and Efficacy of Oral Deucrictibant for Treatment of Upper Airway and Laryngeal Hereditary Angioedema Attacks: Results from the RAPIDe-2 Extension Study Presenter: Ramón Lleonart , M.D. Format: Poster Presentation, P-55 Date, time: Saturday, May 31 , 16:15-17:45 CEST ( 10:15-11:45 a.m. ET ) Title: Epidemiology of Bradykinin-Mediated Angioedema in the European Population Presenter: Emel Aygören-Pürsün, M.D. Format: Poster Presentation, P-30 Date, time: Saturday, May 31 , 16:15-17:45 CEST ( 10:15-11:45 a.m. ET ) 2025 Eastern Allergy Conference , Palm Beach, Fl. , May 29-June 1, 2025 . Title: Long-Term Safety and Efficacy of Oral Deucrictibant for Prophylaxis in Hereditary Angioedema: Results of the CHAPTER-1 Open-Label Extension Study Presenter: John Anderson , M.D. Format: Poster Presentation Date, time: Friday, May 30 , 9:45-11:00 a.m. ET Title: Long-Term Safety and Efficacy of Oral Deucrictibant for Treatment of Hereditary Angioedema Attacks: Results of the RAPIDe-2 Extension Study Presenter: John Anderson , M.D. Format: Poster Presentation Date, time: Friday, May 30 , 9:45-11:00 a.m. ET EAACI Congress 2025 , Glasgow , June 13-16, 2025 . Title: Clinical Validation of a Novel Kinin Biomarker Assay for Characterization of Bradykinin-Mediated Pathologies in U.S. Subjects with Hereditary Angioedema Presenter: Evangelia Pardali, Ph.D. Format: Flash Talk (e-Poster), Abstract #000949, FT03 Date, time: Friday, June 13 , 13:15-14:45 BST ( 8:15-9:45 a.m. ET ) Title: Long-Term Safety and Efficacy of Oral Deucrictibant for Prophylaxis in Hereditary Angioedema: Results of the CHAPTER-1 Open-Label Extension Study Presenter: Emel Aygören-Pürsün, M.D. Format: Thematic Poster Session (e-Poster and Poster Session) Abstract #000070 Date, time: Saturday, June 14 , 12:00-13:00 BST ( 7:00-8:00 a.m. ET ) Title: Long-Term Safety and Efficacy of Oral Deucrictibant for Treatment of Hereditary Angioedema Attacks: Results of the RAPIDe-2 Extension Study Presenter: Henriette Farkas , M.D., Ph.D., D.Sc . Format: Thematic Poster Session (e-Poster and Poster Session), Abstract #000069 Date, time: Saturday, June 14 , 12:00-13:00 BST ( 7:00-8:00 a.m. ET ) Title: Development of a Conceptual Model Supporting a Clinical Outcome Assessment Strategy for Acquired Angioedema due to C1 Inhibitor Deficiency Presenter: Andrea Zanichelli , M.D., Ph.D. Format: Thematic Poster Session (e-Poster and Poster Session), Abstract #000331 Date, time: Sunday, June 15 , 12:45-13:45 BST ( 7:45-8:45 a.m. ET ) Title: Safety and Efficacy of Oral Deucrictibant for Treatment of Upper Airway and Laryngeal Hereditary Angioedema Attacks: Results from the RAPIDe-2 Extension Study Presenter: Anna Valerieva, M.D., Ph.D. Format: Flash Talk (e-Poster), Abstract #000076, FT16 Date, time: Sunday, June 15 , 14:00-15:30 BST ( 9:00-10:30 a.m. ET ) Title: CHAPTER-3 Phase 3 Trial Design: Efficacy and Safety of the Oral Bradykinin B2 Receptor Antagonist Deucrictibant Extended-Release Tablet for Prophylaxis of Hereditary Angioedema Attacks Presenter: William Lumry , M.D. Format: Flash Talk (e-Poster), Abstract #000068, FT16 Date, time: Sunday, June 15 , 14:00-15:30 BST ( 9:00-10:30 a.m. ET ) Title: Long-Term Prophylactic Treatment with Oral Deucrictibant Improves Disease Control and Health-Related Quality of Life in Participants with Hereditary Angioedema in the CHAPTER-1 Open-Label Extension Study Presenter: Markus Magerl , M.D. Format: Flash Talk (e-Poster), Abstract #000075, FT16 Date, time: Sunday, June 15 , 14:00-15:30 BST ( 9:00-10:30 a.m. ET ) Title: Health-Related Quality of Life and Clinical Characteristics in People Living with Hereditary Angioedema Prescribed Long Term Prophylaxis Alone and On-Demand Treatment Alone Presenter: Laurence Bouillet , M.D., Ph.D. Format: Oral Presentation, Abstract #000044, OAS18 Date, time: Sunday, June 15 , 15:45-17:15 BST ( 10:45 a.m.-12:15 p.m. ET ) The posters and presentation slides will be made available on the Investors section of the Pharvaris website at the beginning of the respective presentations at: https://ir.pharvaris.com/news-events/events-presentations . About Pharvaris Pharvaris is a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to potentially address all types of bradykinin-mediated angioedema. Pharvaris intends to provide injectable-like efficacy™ and placebo-like tolerability with the convenience of an oral therapy to prevent and treat bradykinin-mediated angioedema attacks. With positive data in both Phase 2 prophylaxis and on-demand studies in HAE, Pharvaris is currently evaluating the efficacy and safety of deucrictibant in a pivotal Phase 3 study for the prevention of HAE attacks (CHAPTER-3) and a pivotal Phase 3 study for the on-demand treatment of HAE attacks (RAPIDe-3). For more information, visit https://pharvaris.com/ . Contact Maggie Beller Executive Director, Head of Corporate and Investor Communications [email protected] Source: Pharvaris N.V.